Opinion
Video
Author(s):
Stephanie Graff, MD, concludes the discussion with thoughts on endocrine therapies in development for patients with ER+/HER2- metastatic breast cancer.
FDA Approves Datopotamab Deruxtecan for HR-Positive/HER2-Negative Metastatic Breast Cancer
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
Identifying Patients With Low-Risk Breast Cancer for De-escalated Therapy
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
Impact of Sexual Counseling on Women With Breast Cancer
Alcohol and Cancer: Murthy’s Urgent Call